Abstract
It is widely accepted that Aβ42 aggregation is a central event in the pathogenesis of Alzheimers disease. Aβ42 oligomers and fibrils cause the breakdown of neural circuits, neuronal death and eventually dementia. There are a number of physiological molecules that can protect Aβ42 from aggregation. Promoting such protective molecules and mechanisms against Aβ42 aggregation may be a novel direction in AD drug discovery. One of the most striking protective molecules is none other than Aβ40, which inhibits Aβ42 aggregation in a specific and dosage dependent manner. Aβ40 is a critical, built-in mechanism against Aβ42 aggregation. A number of other molecules and mechanisms also inhibit Aβ42 aggregation, such as heat shock proteins, L-PGDS, heme and methionine oxidation. The relevance of these protective mechanisms to AD pathogenesis and intervention is discussed.
Keywords: Amyloid-β peptide (Aβ), Alzheimer's disease (AD), protection, Aβ42 aggregation, Aβ40, NMR, heat shock protein, L-PGDS, heme, methionine oxidation
Current Alzheimer Research
Title: Protection Mechanisms Against Aβ42 Aggregation
Volume: 5 Issue: 6
Author(s): Y. Yan and C. Wang
Affiliation:
Keywords: Amyloid-β peptide (Aβ), Alzheimer's disease (AD), protection, Aβ42 aggregation, Aβ40, NMR, heat shock protein, L-PGDS, heme, methionine oxidation
Abstract: It is widely accepted that Aβ42 aggregation is a central event in the pathogenesis of Alzheimers disease. Aβ42 oligomers and fibrils cause the breakdown of neural circuits, neuronal death and eventually dementia. There are a number of physiological molecules that can protect Aβ42 from aggregation. Promoting such protective molecules and mechanisms against Aβ42 aggregation may be a novel direction in AD drug discovery. One of the most striking protective molecules is none other than Aβ40, which inhibits Aβ42 aggregation in a specific and dosage dependent manner. Aβ40 is a critical, built-in mechanism against Aβ42 aggregation. A number of other molecules and mechanisms also inhibit Aβ42 aggregation, such as heat shock proteins, L-PGDS, heme and methionine oxidation. The relevance of these protective mechanisms to AD pathogenesis and intervention is discussed.
Export Options
About this article
Cite this article as:
Yan Y. and Wang C., Protection Mechanisms Against Aβ42 Aggregation, Current Alzheimer Research 2008; 5 (6) . https://dx.doi.org/10.2174/156720508786898460
DOI https://dx.doi.org/10.2174/156720508786898460 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Frontotemporal Dementia Caused by CHMP2B Mutations
Current Alzheimer Research Targeting Neurotrophic Signal Transduction Pathways in the Treatment of Mood Disorders
Current Signal Transduction Therapy Serum Cytokine Profile in Alzheimer's Disease Patients After Ingestion of an Antioxidant Beverage
CNS & Neurological Disorders - Drug Targets Multipotent, Permeable Drug ASS234 Inhibits Aβ Aggregation, Possesses Antioxidant Properties and Protects from Aβ-induced Apoptosis In Vitro
Current Alzheimer Research Treatment of Catatonia with Asenapine in a Patient with Schizotypal Personality Disorder, Psychotic Depression and Septic Shock from SARSCoV- 2 - A Case Report
CNS & Neurological Disorders - Drug Targets Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine The Endocannabinoid System and Schizophrenia: Integration of Evidence
Current Pharmaceutical Design Meningococcal Disease and Future Drug Targets
CNS & Neurological Disorders - Drug Targets A Peptide Based Pro-Drug Ameliorates Amyloid-β Induced Neuronal Apoptosis in In Vitro SH-SY5Y Cells
Current Alzheimer Research Choline Nutrition Programs Brain Development Via DNA and Histone Methylation
Central Nervous System Agents in Medicinal Chemistry Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design Role of Hexokinase and VDAC in Neurological Disorders
Current Molecular Pharmacology The Impact of Marijuana Use on Memory in HIV-Infected Patients: A Comprehensive Review of the HIV and Marijuana Literatures
Current Drug Abuse Reviews Alzheimer’s Disease and the Early Signs of Age-Related Macular Degeneration
Current Alzheimer Research Neurobiology of Sleep Disturbances in Neurodegenerative Disorders
Current Pharmaceutical Design Non-Steroidal Anti-Inflammatory Drugs and Alzheimers Disease: The Epidemiological Evidence
CNS & Neurological Disorders - Drug Targets Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer’s Disease
Current Pharmaceutical Design Intravenous Immunoglobulins for Alzheimer's Disease
Current Alzheimer Research Cerebral Aneurysm Formation in Nitric Oxide Synthase-3 Knockout Mice
Current Neurovascular Research Processing of Amyloid Precursor Protein and Amyloid Peptide Neurotoxicity
Current Alzheimer Research